secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGC Pharma, Inc. (IGC)
CIK:        0001326205
Form:       8-K
Filed at:   2024-08-02T23:59:59+00:00
Accession:  0001185185-24-000755
Event type: debt
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IGC Pharma extends loan agreement with O-Bank; facility fees cut to $84,000 from $120,000
--------------------------------------------------------------------------------

- Extension effective July 8, 2024, extends term of existing Master Loan and Security Agreement under same terms.
- Facility fees reduced to $84,000 from $120,000; no other material changes to the agreement.
- The loan agreement was previously disclosed in July 2023 8-K; this amendment solely extends the term.
- No new borrowing or change in principal amount; obligation remains under existing credit facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326205/000118518524000755/0001185185-24-000755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326205/000118518524000755/igc20240802_8k.htm
  HTML page:      https://secwatch.observer/filing/0001185185-24-000755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer